Nuvation Bio Inc - Ordinary Shares - Class A
NUVB
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.01B
Close$
$1.32
79.6% downside
Current Fair Value
79.6% downsideOvervalued by 79.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.01 Billion |
|---|---|
| Enterprise Value | $1.90 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.6 |
| Beta | 1.53 |
| Outstanding Shares | 347,332,000 |
Return
| Return on Equity | -45.69% |
|---|---|
| Return on Assets | -23.92% |
| Return on Invested Capital | -26.58% |
Valuation & Multiples
| P/E Ratio | -13.66 |
|---|---|
| PEG | 12.41 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 13.27 |
| Enterprise Value to EBIT | -13.46 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$61.65 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$26.37 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 52.01% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.38%▼ 64.19% |
|---|---|
| Total Invested | $7.48M▼ 99.21% |
| Investors Holding | 18▼ 219.00% |
ESG Score
No data
About Nuvation Bio Inc
36 employeesNuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically ...